For more informations, visit: [ Ссылка ] Scientists have made great strides to improve cellular models that permit high-throughput screens to identify and characterize therapeutic candidates. For example, researchers now derive cardiomyocytes from human pluripotent stem cells (PSCs) to study a compound’s effect on cardiac function. To guarantee the experimental success and reproducibility of PSC-based high-throughput screens, researchers must apply good PSC culturing practices, ensure consistent and efficient differentiation, and incorporate quality controls at various steps. In this webinar, brought to you by Miltenyi Biotec, experts will present a complete workflow to perform high-throughput screens with PSC-derived cardiomyocytes.
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies enable solutions for cellular research, cell therapy, cell manufacturing, and imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
